Synapse - Works

Results (2639)

Updated analyses of the international, open-label, randomized, phase 3 alcanza study: Longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL)

Meeting Abstract

Horwitz, S. M.; Scarisbrick, J. J.; Dummer, R.; Duvic, M.; Kim, Y. H.; Walewski, J.; Whittaker, S.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; more...
Blood (2017)

Fulltext@MSK | Save

Results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Meeting Abstract

Herrera, A. F.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; LaCasce, A. S.; Ansell, S. M.; Moskowitz, C. H.; Fenton, K.; more...
Blood (2017)

Fulltext@MSK | Save

Burkitt Lymphoma Genome Sequencing Project (BLGSP): Integrative genomic and transcriptomic characterization of Burkitt lymphoma

Meeting Abstract

Grande, B. M.; Gerhard, D. S.; Griner, N. B.; Casper, C.; Namirembe, C.; Omoding, A.; Orem, J.; Mbulaiteye, S. M.; Mullighan, C. G.; Sandlund, J. T.; more...
Blood (2017)

Fulltext@MSK | Save

Natural history of hypogammaglobulinemia in patients with follicular lymphoma and the impact of anti-CD20-based therapy

Meeting Abstract

Fischer, T.; Ni, A.; Soumerai, J. D.; Alperovich, A.; Batlevi, C. L.; Younes, A.; Zelenetz, A. D.
Blood (2017)

Fulltext@MSK | Save

Generation and application of T-cell lymphoma patient derived tumor xenograft models

Meeting Abstract

Fiore, D.; Wang, X.; Khodos, I.; Di Giacomo, F.; Gaudiano, M.; Phillip, J. M.; Wang, R.; Yang, Z.; Ginsberg, M.; Intlekofer, A. M.; more...
Blood (2017)

Fulltext@MSK | Save

Maximum tolerated dose (MTD) and safety profile from phase I study of MT-3724 (CD20 targeted immunotoxin) in relapsed/refractory (R/R) non-Hodgkin B-cell lymphoma (NHL)

Meeting Abstract

Fanale, M. A.; Park, S. I.; Valacer, D. J.; Higgins, J.; Sloan, J. M.; Younes, A.; Hamlin, P. A.
Blood (2017)

Fulltext@MSK | Save

Five-year survival results: Frontline brentuximab vedotin in combination with CHP in patients with CD30-expressing peripheral T-cell lymphomas

Meeting Abstract

Fanale, M. A.; Horwitz, S. M.; Forero-Torres, A.; Bartlett, N. L.; Advani, R. H.; Pro, B.; Chen, R. W.; Davies, A.; Illidge, T. M.; Uttarwar, M.; more...
Blood (2017)

Fulltext@MSK | Save

Sequential brentuximab vedotin (Bv) before and after adriamycin, vinblastine, and dacarbazine (Bv-AVD) for older patients with untreated classical Hodgkin lymphoma (cHL): Final results from a multicenter phase II study

Meeting Abstract

Evens, A. M.; Advani, R. H.; Fanale, M. A.; Smith, S. M.; Helenowski, I.; Jovanovic, B.; Bociek, R. G.; Klein, A.; Winter, J. N.; Gordon, L. I.; more...
Blood (2017)

Fulltext@MSK | Save

Nivolumab treatment beyond investigator-assessed progression: Outcomes in patients with relapsed/refractory classical Hodgkin lymphoma from the phase 2 CheckMate 205 study

Meeting Abstract

Cohen, J. B.; Engert, A.; Ansell, S. M.; Younes, A.; Trneny, M.; Savage, K. J.; Ramchandren, R.; Collins, G.; Fanale, M. A.; Armand, P.; more...
Blood (2017)

Fulltext@MSK | Save

Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): The phase 3 ECHELON-1 study

Meeting Abstract

Connors, J. M.; Jurczak, W.; Straus, D. J.; Ansell, S. M.; Kim, W. S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illes, A.; Picardi, M.; more...
Blood (2017)

Fulltext@MSK | Save